Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more. https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y